In today’s briefing:
- Royalty Pharma: These Are The Major Shifts That Could Redefine Biopharma Royalties!
- Genuine Biotech (真实生物) Pre-IPO Tearsheet
- Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!
- GRCE: STRIVE-ON Results Reported
- GRAIL’s 4Q’FY24 Financial Results: The Company Is On Track To Complete FDA/PMA Submission In FY26
- TELO: Test Results Open Huge Market Potential
Royalty Pharma: These Are The Major Shifts That Could Redefine Biopharma Royalties!
- Royalty Pharma has reported robust financial results for the fourth quarter and full year 2024, underscoring its position as a leading funder of innovation within the life sciences sector.
- With a significant emphasis on strategic capital deployment, Royalty Pharma achieved portfolio receipts of $2.8 billion, marking a commendable 13% growth and surpassing initial guidance expectations of 5% to 9%.
- This financial performance reflects the company’s adept management and its capacity to expand its portfolio effectively.
Genuine Biotech (真实生物) Pre-IPO Tearsheet
- Genuine Biotech is looking to raise at least US$100 million via a Hong Kong listing.
- Genuine Biotech has commercialized product and is expanding indication of its core product from HIV to cancer.
- The company’s founder has experience of R&D in the relevant area in leading NMCs.
Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!
- Exelixis reported a robust performance for the fourth quarter and fiscal year 2024, highlighting significant financial growth and ongoing developments in their oncology portfolio.
- The company’s total revenues for the fourth quarter reached approximately $567 million, driven by the strong performance of the cabozantinib franchise, specifically CABOMETYX, which achieved net product revenues of $515.2 million.
- For the full year 2024, Exelixis reported U.S. cabo franchise net product revenues of $1.81 billion, reflecting substantial year-over-year growth.
GRCE: STRIVE-ON Results Reported
- Grace is a clinical-stage, biotechnology company focused on rare disease.
- Its lead program, GTX-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).
- Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia.
GRAIL’s 4Q’FY24 Financial Results: The Company Is On Track To Complete FDA/PMA Submission In FY26
- GRAIL shares outperformed the market in 2025 with shares up ~168% year-to-date vs. a modest ~3% gain on the Nasdaq Composite.
- Most notably, management disclosed that Quest Diagnostics and TRICARE Health Insurance expanded their relationships with GRAIL.
- A fast-growing healthcare company reported FY24 revenues of ~$126M, up ~35% year-over-year, and ended 4Q’FY24 with ~$767M of cash and cash equivalents.
TELO: Test Results Open Huge Market Potential
- Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.
- The company released test results that showed Telomir-1 captured and stabilized the highly reactive Silver(II) in a biologically compatible form.
- This creates the potential for entry into a multi-billion-dollar market.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
